Item no. |
HY-P1333-1mg |
Manufacturer |
MedChem Express
|
CASRN |
80448-90-4 |
Amount |
1 mg |
Quantity options |
10 mg
1 mg
5 mg
|
Category |
|
Type |
Peptides |
Specific against |
other |
Purity |
98.59 |
Formula |
C99H155N31O23 |
Citations |
[1]Zhang, et al.Dynorphin A as a Potential Endogenous Ligand for Four Members of the Opioid Receptor Gene Family. J Pharmacol Exp Ther. 1998 Jul;286(1):136-41.<br/>[2]Aruna Sharma, et al. Monoclonal antibodies as novel neurotherapeutic agents in CNS injury and repair. Int Rev Neurobiol. 2012;102:23-45. <br/>[3]I. N. SINGH, et al. Dynorphin A (1–17) induces apoptosis in striatal neurons in vitro through AMPA/kainate receptor-mediated cytochrome c release and caspase-3 activation. Neuroscience. 2003;122(4):1013-23. <br/>[4]K F Hauser, et al. Dynorphin A (1-13) neurotoxicity in vitro: opioid and non-opioid mechanisms in mouse spinal cord neurons. Exp Neurol. 1999 Dec;160(2):361-75. <br/>[5]B J Van de Heijning, et al. Dynorphin-A and vasopressin release in the rat: a structure-activity study. Neuropeptides. 1994 Jun;26(6):371-8. <br/>[6]Takayoshi Mamiya, et al. Dynorphin a (1-13) alleviated stress-induced behavioral impairments in mice. Biol Pharm Bull. 2014;37(8):1269-73. |
Smiles |
O=C([C@H]1N(CCC1)C([C@H](CCCNC(N)=N)NC([C@H]([C@@H](C)CC)NC([C@H](CCCNC(N)=N)NC([C@H](CCCNC(N)=N)NC([C@H](CC(C)C)NC([C@@H](NC(CNC(CNC([C@@H](N)CC2=CC=C(C=C2)O)=O)=O)=O)CC3=CC=CC=C3)=O)=O)=O)=O)=O)=O)N[C@@H](CCCCN)C(N[C@@H](CC(C)C)C(N[C@@H](CCCCN)C(N[C@H](C(N[C@@H](CC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@H](C(O)=O)CCC(N)=O)=O)=O)=O)CC4=CNC5=CC=CC=C45)=O)=O)=O |
ECLASS 10.1 |
32160409 |
ECLASS 11.0 |
32160409 |
UNSPSC |
12352202 |
Alias |
80448-90-4 |
Similar products |
80448-90-4 |
Available |
|
Product Description |
Dynorphin A is an endogenous opioid peptide involved in inhibitory neurotransmission in the central nervous system (CNS). Dynorphin A is a highy potent kappa opioid receptor (KOR) agonist, and is also an agonist for other opioid receptors, such as mu (MOR) and delta (DOR). Dynorphin A can induce neuronal death, and can be used in the research of neurological disease[1][2]. |
StorageTemperature |
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light) |
Shipping |
Blue Ice |
Manufacturers Applications |
Neuroscience-Neuromodulation |
MolecularWeight |
2147.48 |
Clinical Information |
Phase 2 |
Manufacturers Research Area |
Neurological Disease |
Solubility |
DMSO : 100 mg/mL (ultrasonic)|H2O : ≥ 100 mg/mL |
Target |
Apoptosis; Caspase; Endogenous Metabolite; Opioid Receptor |
Manufacturers Target |
Apoptosis; Caspase; Endogenous Metabolite; Opioid Receptor |
Isoform |
Caspase 3; Human Endogenous Metabolite; κ Opioid Receptor/KOR |
Manufacturers Pathway |
Apoptosis; GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling |
Manufacturers Product type |
Peptides |
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.